title: The immune checkpoint inhibitors: where are we now?
authors.affiliation: Decision Resources, 6th Floor, Aldermary House, 1015 Queen Street, London EC4N 1TX, United Kingdom.
authors.forename: Rachel M
authors.initials: RM
authors.lastname: Webster
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors* / Q000276:immunology; D002986:Clinical Trials as Topic / Q000639:trends; D055808:Drug Discovery / Q000639:trends*; D006801:Humans; D000074324:Ipilimumab; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors* / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D000074324:Ipilimumab; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab; C582435:pembrolizumab